Insulet Corp（PODD）股票分析PODDInsulet Corp

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Insulet Corp (PODD) appears to be a good buy right now due to its current price of $149.01, which is below the average analyst price target of $190, suggesting a potential upside of approximately 27.5%. Additionally, the RSI is at 80.953, indicating strong momentum, while the company has shown a 5-day price increase of 5.61%. However, the main risk is the forward P/E ratio of 54.9451, which suggests that the stock may be overvalued if growth does not meet expectations.

17 analysts cover PODD: 10 rate it Buy, 7 Hold and 0 Sell. The average price target is 375.83.